Affordable Access

Access to the full text

Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins

Authors
  • Loya, Joshua1
  • Zhang, Charlie2
  • Cox, Emily3
  • Achrol, Achal S4
  • Kesari, Santosh4
  • 1 Wayne State University School of Medicine, Department of Neurosurgery, 42 W Warren Ave, Detroit, MI 48202, USA
  • 2 State University of New York at Buffalo School of Medicine, 1010 Main St, Buffalo, NY 14202, USA
  • 3 Providence Medical Research Center, 105 W 8th Ave #6050w, Spokane, WA 99204, USA
  • 4 John Wayne Cancer Institute & Pacific Neuroscience Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
Type
Published Article
Journal
CNS Oncology
Publisher
Future Medicine
Publication Date
Nov 21, 2019
Volume
8
Issue
3
Identifiers
DOI: 10.2217/cns-2019-0001
PMID: 31747788
PMCID: PMC6880302
Source
PubMed Central
Keywords
License
Green

Abstract

Management of high-grade gliomas remains a complex challenge. Standard of care consists of microsurgical resection, chemotherapy and radiation, but despite these aggressive multimodality therapies the overall prognosis remains poor. A major focus of ongoing translational research studies is to develop novel therapeutic strategies that can maximize tumor cell eradication while minimizing collateral side effects. Particularly, biological intratumoral therapies have been the focus of new translational research efforts due to their inherent potential to be both dynamically adaptive and target specific. This two-part review will provide an overview of biological intratumoral therapies and summarize key advances and remaining challenges in intratumoral biological therapies for high-grade glioma. Part I focuses on discussion of the concepts of intratumoral delivery and immunotoxin therapies.

Report this publication

Statistics

Seen <100 times